Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Allergan Plc (AGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,998,808
  • Shares Outstanding, K 327,802
  • Annual Sales, $ 15,787 M
  • Annual Income, $ -5,096,400 K
  • 60-Month Beta 1.39
  • Price/Sales 2.51
  • Price/Cash Flow 3.27
  • Price/Book 0.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 4.28
  • Number of Estimates 12
  • High Estimate 4.37
  • Low Estimate 4.20
  • Prior Year 4.42
  • Growth Rate Est. (year over year) -3.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.27 +1.28%
on 06/17/19
140.13 -17.41%
on 05/22/19
-24.47 (-17.45%)
since 05/17/19
3-Month
114.27 +1.28%
on 06/17/19
155.51 -25.58%
on 03/21/19
-35.52 (-23.48%)
since 03/15/19
52-Week
114.27 +1.28%
on 06/17/19
197.00 -41.25%
on 10/03/18
-57.45 (-33.17%)
since 06/15/18

Most Recent Stories

More News
Downtrend Call Working As Allergan Plc Stock Falls 19.1% (AGN)

SmarTrend identified a Downtrend for Allergan Plc (NYSE:AGN) on April 15th, 2019 at $143.76. In approximately 2 months, Allergan Plc has returned 19.12% as of today's recent price of $116.28.

AGN : 115.73 (-0.16%)
Medical Aesthetics Market Devices, Product Diversification, Development Opportunities and Global Industry Share Analysis by Top Leading Competitors - Latest MRFR Brief 2019

VRX.TO : 30.80 (-3.33%)
HOLX : 47.79 (-0.10%)
AGN : 115.73 (-0.16%)
SIEN : 6.71 (+3.71%)
ELOS : 11.00 (unch)
Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti

FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.

AGN : 115.73 (-0.16%)
RHHBY : 34.4400 (-0.32%)
AMGN : 178.39 (+1.31%)
PFE : 42.88 (+0.28%)
FDA Approves Amgen And Allergan's KANJINTI(TM) (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI(TM) (trastuzumab-anns) for all approved indications of the reference...

AGN : 115.73 (-0.16%)
AMGN : 178.39 (+1.31%)
Medical Aesthetics Market Size, Analysis, Top Vendors, Market Status and Forecasts to 2026

Medical Aesthetics Market Report (2019-2026)

VRX.TO : 30.80 (-3.33%)
ANIK : 40.52 (+1.89%)
HOLX : 47.79 (-0.10%)
AGN : 115.73 (-0.16%)
SIEN : 6.71 (+3.71%)
ELOS : 11.00 (unch)
2019 Update: Ophthalmic Drugs Market Global Statistics and Forecast Till 2028

MarketResearch.Biz provide a 10-year forecast for the Ophthalmic Drugs market between 2019 and 2028. The study serves key trends that are presently impressing the growth of the Ophthalmic Drugs market....

VRX.TO : 30.80 (-3.33%)
SNPHF : 15.1500 (+2.02%)
AGN : 115.73 (-0.16%)
NVS : 89.76 (+0.27%)
SHPG : 179.20 (+4.10%)
TEVA : 8.20 (-0.49%)
REGN : 310.98 (+1.88%)
Allergan Plc Falls 2.31% on Heavy Volume: Watch For Potential Rebound

Allergan Plc (NYSE:AGN) traded in a range yesterday that spanned from a low of $123.44 to a high of $126.65. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $124.67...

AGN : 115.73 (-0.16%)
TherapeuticsMD Enters Agreement to Market Drugs Outside US

TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.

AGN : 115.73 (-0.16%)
AMAG : 9.04 (+0.56%)
TXMD : 2.66 (+9.02%)
PFE : 42.88 (+0.28%)
Allergan Launches Dr. Jacob Unger's Breast Reconstruction Invention Fourte for Use in 2019

Dr. Jacob Unger is proud to announce that his invention, Fourte, officially launched at Allergan's national sales meeting earlier this year. The plastic surgeon at Nashville, TN's Maxwell Aesthetics drew...

AGN : 115.73 (-0.16%)
Global (United States, European Union and China) Inflammatory Bowel Disease Treatment Market Research Report 2019-2025

In 2019, the market size of Inflammatory Bowel Disease Treatment is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million...

VRX.TO : 30.80 (-3.33%)
AGN : 115.73 (-0.16%)
NVS : 89.76 (+0.27%)
TKPYY : 16.5900 (-0.90%)
ABBV : 78.65 (-0.05%)
PFE : 42.88 (+0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade AGN with:

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Key Turning Points

2nd Resistance Point 118.97
1st Resistance Point 117.35
Last Price 115.73
1st Support Level 114.19
2nd Support Level 112.65

See More

52-Week High 197.00
Fibonacci 61.8% 165.40
Fibonacci 50% 155.63
Fibonacci 38.2% 145.87
Last Price 115.73
52-Week Low 114.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar